收藏切换
Mesenchymal stem cells and extracellular vesicles: multidimensional therapeutic mechanisms and engineered breakthroughs targeting pulmonary fibrosis
收藏切换
Weili FENG1, 2, 3, Li LIU1, 2, 3, Yifang DENG1, 2, 3, *
World Clinical Drug | 2026, 47(5) : 560 - 567
Less
收藏切换
World Clinical Drug | 2026, 47(5): 560-567
• Review •
Mesenchymal stem cells and extracellular vesicles: multidimensional therapeutic mechanisms and engineered breakthroughs targeting pulmonary fibrosis
Full
Weili FENG1, 2, 3, Li LIU1, 2, 3, Yifang DENG1, 2, 3, *
Affiliations
  • 1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China
  • 2.National Key Laboratory of Pharmacogenicity Research of Pioneers, Shanghai 200437, China
  • 3.Shanghai Professional and Technical Service Center for Biological Material Drug-Ability Evaluation, Shanghai 200437, China
Published: 2026-05-10 doi: 10.13683/j.wph.2026.05.016
Outline
收藏切换

Pulmonary fibrosis is a chronic progressive interstitial lung disease induced by multiple factors such as environmental exposure, infections. Its core pathological features are abnormal extracellular matrix deposition and myofibroblast over-activation. The efficacy of currently available therapeutic agents is limited, as they lack sufficient targeting capacity and are unable to reverse the progression of fibrosis. In recent years, pluripotent mesenchymal stem cells(MSCs) and their secreted extracellular vesicles(especially exosomes) have shown breakthrough potential in the treatment of pulmonary fibrosis due to their unique tissue repair and immunomodulatory functions. This article systematically reviewed the multidimensional antifibrotic mechanisms of MSCs and their extracellular vesicles(exosomes), deeply explored the engineered modification strategies(such as gene modification, novel vectors and delivery systems, and combined interventions) in enhancing therapeutic efficacy, and analyzed the challenges of translating from basic research to the clinic,in order to provide theoretical basis for the research of new anti-fibrosis drugs and the clinical application of MSCs.

mesenchymal stem cells  /  extracellular vesicles  /  exosomes  /  pulmonary fibrosis  /  engineering modifications
冯伟莉, 刘莉, 邓轶方. 间充质干细胞及细胞外囊泡:靶向肺纤维化的多维治疗机制及工程化突破. 世界临床药物, 2026 , 47 (5) : 560 -567 . DOI: 10.13683/j.wph.2026.05.016
Weili FENG, Li LIU, Yifang DENG. Mesenchymal stem cells and extracellular vesicles: multidimensional therapeutic mechanisms and engineered breakthroughs targeting pulmonary fibrosis[J]. World Clinical Drug, 2026 , 47 (5) : 560 -567 . DOI: 10.13683/j.wph.2026.05.016
Year 2026 volume 47 Issue 5
61
12
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.05.016
  • Receive Date:2025-09-02
  • Online Date:2026-11-05
  • Published:2026-05-10
Article Data
Affiliations
History
  • Received:2025-09-02
Funding
Affiliations
    1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China
    2.National Key Laboratory of Pharmacogenicity Research of Pioneers, Shanghai 200437, China
    3.Shanghai Professional and Technical Service Center for Biological Material Drug-Ability Evaluation, Shanghai 200437, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.05.016
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT